Past Collaborations
My Services
Innovative consulting solutions to achieve impactful results
As a seasoned consultant for the pharmaceutical industry and an active member of multiple advisory boards, Dr. Isaacs provides strategic insights for cutting-edge diabetes solutions and ensures the highest standards in diabetes care.
As a seasoned consultant for the pharmaceutical industry and an active member of multiple advisory boards, Dr. Isaacs provides strategic insights for cutting-edge diabetes solutions and ensures the highest standards in diabetes care.
An authority in diabetes content
With over 80 peer reviewed publications, Dr. Isaacs stands as a leading authority in diabetes content.
Offering expert writing services, she has repeatedly transformed diabetes research and clinical practice insights into engaging manuscripts, reports, and educational materials.
Elevating diabetes care through compelling speaking engagements
Dr. Isaacs is renowned for her captivating speaking engagements that educate and inspire clinicians and patient advocates.
She has been a speaker for leading organizations including the American Diabetes Association, the Association of Diabetes Care and Education Specialists, the American Association of Clinical Endocrinology, and the American Heart Association.
In addition, she frequently delivers continuing medical education (CME) programs to equip providers with the latest knowledge and skills.
What I've Been Working on
Consulting
Speaking
Medical Writing
CME
My Expertise
Recent Presentations
Recent Publications
Recent Podcasts
Videos
X Timeline
A timely JAMA Research Letter suggests that if Medicare Part D plans adopt the BALANCE model, semaglutide at $245/month could generate ~$933M in savings vs 2027 IRA-negotiated pricing—enough to offset treatment for ~549,000 additional Medicare beneficiaries eligible for
Excited to be speaking this Thursday at the San Francisco Marriott Marquis (Yerba Buena Ballroom, Salon 7) from 6–8 PM on CGM and diabetes tech. Dinner and CME will be provided, explore more here: #CME #CGM #gotoPER
The American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Management of Adults with Type 2 Diabetes - 2026 Update provides evidence-based visual guidance and key considerations for the diagnosis and management of adults with prediabetes and
The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults with type 2 diabetes, developer Novo Nordisk announced.